The chemical chaperon 4-phenylbutyrate inhibits adipogenesis by modulating the unfolded protein response

Journal of Lipid Research

Volumn 50, Issue 12, 2009, Pages 2486-2501

  Basseri, Sana ^a   Lhoták, Šárka ^a   Sharma, Arya M ^b   Austin, Richard C ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b ROYAL ALEXANDRA HOSPITAL   (Canada)

Author keywords

3T3 L1; Adipocyte differentiation; ER stress; Obesity

Indexed keywords

4 PHENYLBUTYRIC ACID; ADIPONECTIN; GLUCOSE REGULATED PROTEIN 78; 4-PHENYLBUTYRIC ACID; ARYLBUTYRIC ACID DERIVATIVE; DNA BINDING PROTEIN; REGULATORY FACTOR X TRANSCRIPTION FACTORS; TRANSCRIPTION FACTOR;

ADIPOCYTE; ADIPOGENESIS; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CHEMICAL ANALYSIS; CONTROLLED STUDY; ENDOPLASMIC RETICULUM STRESS; FEMALE; FOOD INTAKE; GENE ACTIVATION; LIPOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; UPREGULATION; ANIMAL; BODY WEIGHT; C57BL MOUSE; CELL CULTURE; CELL STRAIN 3T3; CHEMISTRY; CYTOLOGY; DIET SUPPLEMENTATION; DRUG EFFECT; ENDOPLASMIC RETICULUM; METABOLISM; PROTEIN FOLDING;

3T3-L1 CELLS; ADIPOCYTES; ADIPOGENESIS; ANIMALS; BODY WEIGHT; CELLS, CULTURED; DIETARY SUPPLEMENTS; DNA-BINDING PROTEINS; ENDOPLASMIC RETICULUM; FEMALE; MICE; MICE, INBRED C57BL; PHENYLBUTYRATES; PROTEIN FOLDING; TRANSCRIPTION FACTORS;

EID: 68949214283     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M900216-JLR200     Document Type: Article

References (81)

1. Bray, G. A. 2004. Medical consequences of obesity. J. Clin. Endocrinol. Metab. 89: 2583-2589.
2. Kosti, R. I., and D. B. Panagiotakos. 2006. The epidemic of obesity in children and adolescents in the world. Cent. Eur. J. Public Health. 14: 151-159.
3. Gregoire, F. M., C. M. Smas, and H. S. Sul. 1998. Understanding adipocyte differentiation. Physiol. Rev. 78: 783-809.
4. Erol, A. 2005. Adipocyte insensitivity syndromes-novel approach to nutritional metabolic problems including obesity and obesity related disorders. Med. Hypotheses. 64: 826-832.
5. de Ferranti, S., and D. Mozaffarian. 2008. The perfect storm: obesity, adipocyte dysfunction, and metabolic consequences. Clin. Chem. 54: 945-955.
6. Green, H., and O. Kehinde. 1975. An established preadipose cell line and its differentiation in culture. II. Factors affecting the adipose conversion. Cell. 5: 19-27.
7. Kim, S., and N. Moustaid-Moussa. 2000. Secretory, endocrine and autocrine/paracrine function of the adipocyte. J. Nutr. 130: 3110S-3115S.
8. Kim, P. S., and P. Arvan. 1998. Endocrinopathies in the family of endoplasmic reticulum (ER) storage diseases: disorders of protein traffi cking and the role of ER molecular chaperones. Endocr. Rev. 19: 173-202.
9. Schroder, M., and R. J. Kaufman. 2005. The mammalian unfolded protein response. Annu. Rev. Biochem. 74: 739-789.
10. Ozcan, U., Q. Cao, E. Yilmaz, A. H. Lee, N. N. Iwakoshi, E. Ozdelen, G. Tuncman, C. Gorgun, L. H. Glimcher, and G. S. Hotamisligil. 2004. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science. 306: 457-461.
11. Gregor, M. F., and G. S. Hotamisligil. 2007. Thematic review series: Adipocyte Biology. Adipocyte stress: the endoplasmic reticulum and metabolic disease. J. Lipid Res. 48: 1905-1914.
12. Shen, X., K. Zhang, and R. J. Kaufman. 2004. The unfolded protein response-a stress signaling pathway of the endoplasmic reticulum. J. Chem. Neuroanat. 28: 79-92.
13. Hendershot, L. M. 2004. The ER function BiP is a master regulator of ER function. Mt. Sinai J. Med. 71: 289-297.
14. Ozcan, U., E. Yilmaz, L. Ozcan, M. Furuhashi, E. Vaillancourt, R. O. Smith, C. Z. Gorgun, and G. S. Hotamisligil. 2006. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science. 313: 1137-1140.
15. Ozawa, K., M. Miyazaki, M. Matsuhisa, K. Takano, Y. Nakatani, M. Hatazaki, T. Tamatani, K. Yamagata, J. Miyagawa, Y. Kitao, et al. 2005. The endoplasmic reticulum chaperone improves insulin resistance in type 2 diabetes. Diabetes. 54: 657-663.
16. Sreejayan, N., F. Dong, M. R. Kandadi, X. Yang, and J. Ren. 2008. Chromium alleviates glucose intolerance, insulin resistance, and hepatic ER stress in obese mice. Obesity (Silver Spring). MD. 16: 1331-1337.
17. Oyadomari, S., H. P. Harding, Y. Zhang, M. Oyadomari, and D. Ron. 2008. Dephosphorylation of translation initiation factor 2alpha enhances glucose tolerance and attenuates hepatosteatosis in mice. Cell Metab. 7: 520-532.
18. Hosogai, N., A. Fukuhara, K. Oshima, Y. Miyata, S. Tanaka, K. Segawa, S. Furukawa, Y. Tochino, R. Komuro, M. Matsuda, et al. 2007. Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes. 56: 901-911.
19. Ozcan, L., A. S. Ergin, A. Lu, J. Chung, S. Sarkar, D. Nie, M. G. Myers, Jr., and U. Ozcan. 2009. Endoplasmic reticulum stress plays a central role in development of leptin resistance. Cell Metab. 9: 35-51.
20. Boden, G., X. Duan, C. Homko, E. J. Molina, W. Song, O. Perez, P. Cheung, and S. Merali. 2008. Increase in endoplasmic reticulum stress-related proteins and genes in adipose tissue of obese, insulin-resistant individuals. Diabetes. 57: 2468-2444.
21. Sharma, N. K., S. K. Das, A. K. Mondal, O. G. Hackney, W. S. Chu, P. A. Kern, N. Rasouli, H. J. Spencer, A. Yao-Borengasser, and S. C. Elbein. 2008. Endoplasmic reticulum stress markers are associated with obesity in nondiabetic subjects. J. Clin. Endocrinol. Metab. 93: 4532-4541.
22. Gregor, M. F., L. Yang, E. Fabbrini, B. S. Mohammed, J. C. Eagon, G. S. Hotamisligil, and S. Klein. 2009. Endoplasmic reticulum stress is reduced in tissues of obese subjects after weight loss. Diabetes. 58: 693-700.
23. Rutkowski, D. T., J. Wu, S. H. Back, M. U. Callaghan, S. P. Ferris, J. Iqbal, R. Clark, H. Miao, J. R. Hassler, J. Fornek, et al. 2008. UPR pathways combine to prevent hepatic steatosis caused by ER stress-mediated suppression of transcriptional master regulators. Dev. Cell. 15: 829-840.
24. Bobrovnikova-Marjon, E., G. Hatzivassiliou, C. Grigoriadou, M. Romero, D. R. Cavener, C. B. Thompson, and J. A. Diehl. 2008. PERK-dependent regulation of lipogenesis during mouse mammary gland development and adipocyte differentiation. Proc. Natl. Acad. Sci. USA. 105: 16314-16319.
25. Yoshida, H., T. Matsui, A. Yamamoto, T. Okada, and K. Mori. 2001. XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. Cell. 107: 881-891.
26. Lee, A. H., E. F. Scapa, D. E. Cohen, and L. H. Glimcher. 2008. Regulation of hepatic lipogenesis by the transcription factor XBP1. Science. 320: 1492-1496.
27. Qi, X., T. Hosoi, Y. Okuma, M. Kaneko, and Y. Nomura. 2004. Sodium 4-phenylbutyrate protects against cerebral ischemic injury. Mol. Pharmacol. 66: 899-908.
28. Ryu, H., K. Smith, S. I. Camelo, I. Carreras, J. Lee, A. H. Iglesias, F. Dangond, K. A. Cormier, M. E. Cudkowicz, R. H. Brown, Jr., et al. 2005. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J. Neurochem. 93: 1087-1098.
29. Inden, M., Y. Kitamura, H. Takeuchi, T. Yanagida, K. Takata, Y. Kobayashi, T. Taniguchi, K. Yoshimoto, M. Kaneko, Y. Okuma, et al. 2007. Neurodegeneration of mouse nigrostriatal dopaminergic system induced by repeated oral administration of rotenone is prevented by 4-phenylbutyrate, a chemical chaperone. J. Neurochem. 101: 1491-1504.
30. Kubota, K., Y. Niinuma, M. Kaneko, Y. Okuma, M. Sugai, T. Omura, M. Uesugi, T. Uehara, T. Hosoi, and Y. Nomura. 2006. Suppressive effects of 4-phenylbutyrate on the aggregation of Pael receptors and endoplasmic reticulum stress. J. Neurochem. 97: 1259-1268.
31. Lim, M., K. McKenzie, A. D. Floyd, E. Kwon, and P. L. Zeitlin. 2004. Modulation of deltaF508 cystic fi brosis transmembrane regulator traffi cking and function with 4-phenylbutyrate and fl avonoids. Am. J. Respir. Cell Mol. Biol. 31: 351-357.
32. Vilatoba, M., C. Eckstein, G. Bilbao, C. A. Smyth, S. Jenkins, J. A. Thompson, D. E. Eckhoff, and J. L. Contreras. 2005. Sodium 4-phenylbutyrate protects against liver ischemia reperfusion injury by inhibition of endoplasmic reticulum-stress mediated apoptosis. Surgery. 138: 342-351.
33. Mulhern, M. L., C. J. Madson, P. F. Kador, J. Randazzo, and T. Shinohara. 2007. Cellular osmolytes reduce lens epithelial cell death and alleviate cataract formation in galactosemic rats. Mol. Vis. 13: 1397-1405.
34. de Almeida, S. F., G. Picarote, J. V. Fleming, M. Carmo-Fonseca, J. E. Azevedo, and M. de Sousa. 2007. Chemical chaperones reduce endoplasmic reticulum stress and prevent mutant HFE aggregate formation. J. Biol. Chem. 282: 27905-27912.
35. Datta, R., A. Waheed, G. N. Shah, and W. S. Sly. 2007. Signal sequence mutation in autosomal dominant form of hypoparathyroidism induces apoptosis that is corrected by a chemical chaperone. Proc. Natl. Acad. Sci. USA. 104: 19989-19994.
36. Sawada, N., J. Yao, N. Hiramatsu, K. Hayakawa, I. Araki, M. Takeda, and M. Kitamura. 2008. Involvement of hypoxia-triggered endoplasmic reticulum stress in outlet obstruction-induced apoptosis in the urinary bladder. Lab. Invest. 88: 553-563.
37. Watanabe, N., and E. Lam. 2008. BAX inhibitor-1 modulates endoplasmic reticulum stress-mediated programmed cell death in Arabidopsis. J. Biol. Chem. 283: 3200-3210.
38. Choi, S. E., Y. J. Lee, H. J. Jang, K. W. Lee, Y. S. Kim, H. S. Jun, S. S. Kang, J. Chun, and Y. Kang. 2008. A chemical chaperone 4-PBA ameliorates palmitate-induced inhibition of glucose-stimulated insulin secretion (GSIS). Arch. Biochem. Biophys. 475: 109-114.
39. Haberzettl, P., E. Vladykovskaya, S. Srivastava, and A. Bhatnagar. 2009. Role of endoplasmic reticulum stress in acrolein-induced endothelial activation. Toxicol. Appl. Pharmacol. 234: 14-24.
40. Hosoi, T., M. Sasaki, T. Miyahara, C. Hashimoto, S. Matsuo, M. Yoshii, and K. Ozawa. 2008. Endoplasmic reticulum stress induces leptin resistance. Mol. Pharmacol. 74: 1610-1619.
41. Kuri-Harcuch, W., and H. Green. 1978. Adipose conversion of 3T3 cells depends on a serum factor. Proc. Natl. Acad. Sci. USA. 75: 6107-6109.
42. Kasturi, R., and V. C. Joshi. 1982. Hormonal regulation of stearoyl coenzyme A desaturase activity and lipogenesis during adipose conversion of 3T3-L1 cells. J. Biol. Chem. 257: 12224-12230.
43. Sauter, N. S., F. T. Schulthess, R. Galasso, L. W. Castellani, and K. Maedler. 2008. The anti-infl ammatory cytokine IL-1Ra protects from high fat diet-induced hyperglycemia. Endocrinology. 149: 2208-2218.
44. Suzawa, M., I. Takada, J. Yanagisawa, F. Ohtake, S. Ogawa, T. Yamauchi, T. Kadowaki, Y. Takeuchi, H. Shibuya, Y. Gotoh, et al. 2003. Cytokines suppress adipogenesis and PPAR-gamma function through the TAK1/TAB1/NIK cascade. Nat. Cell Biol. 5: 224-230.
45. Chae, G. N., and S. J. Kwak. 2003. NF-kappaB is involved in the TNF-alpha induced inhibition of the differentiation of 3T3-L1 cells by reducing PPARgamma expression. Exp. Mol. Med. 35: 431-437.
46. Prestwich, T. C., and O. A. Macdougald. 2007. Wnt/beta-catenin signaling in adipogenesis and metabolism. Curr. Opin. Cell Biol. 19: 612-617.
47. Boyce, M., K. F. Bryant, C. Jousse, K. Long, H. P. Harding, D. Scheuner, R. J. Kaufman, D. Ma, D. M. Coen, D. Ron, et al. 2005. A selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress. Science. 307: 935-939.
48. Sauter, N. S., F. T. Schulthess, R. Galasso, L. W. Castellani, and K. Maedler. 2008. The antiinflammatory cytokine interleukin-1 receptor antagonist protects from high-fat diet-induced hyperglycemia. Endocrinology. 149: 2208-2218.
49. Murano, I., G. Barbatelli, V. Parisani, C. Latini, G. Muzzonigro, M. Castellucci, and S. Cinti. 2008. Dead adipocytes, detected as crown-like structures, are prevalent in visceral fat depots of genetically obese mice. J. Lipid Res. 49: 1562-1568.
50. Subramanian, V., and A. W. Ferrante Jr. 2009. Obesity, infl ammation, and macrophages. Nestle Nutr. Workshop Ser. Pediatr. Program. 63: 151-162.
51. Tordjman, J., M. Guerre-Millo, and K. Clement. 2008. Adipose tissue infl ammation and liver pathology in human obesity. Diabetes Metab. 34: 658-663.
52. Vachharajani, V., and D. N. Granger. 2009. Adipose tissue: a motor for the inflammation associated with obesity. IUBMB Life. 61: 424-430.
53. Iwakoshi, N. N., A. H. Lee, and L. H. Glimcher. 2003. The X-box binding protein-1 transcription factor is required for plasma cell differentiation and the unfolded protein response. Immunol. Rev. 194: 29-38.
54. Iwakoshi, N. N., A. H. Lee, P. Vallabhajosyula, K. L. Otipoby, K. Rajewsky, and L. H. Glimcher. 2003. Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1. Nat. Immunol. 4: 321-329.
55. Reimold, A. M., N. N. Iwakoshi, J. Manis, P. Vallabhajosyula, E. Szomolanyi-Tsuda, E. M. Gravallese, D. Friend, M. J. Grusby, F. Alt, and L. H. Glimcher. 2001. Plasma cell differentiation requires the transcription factor XBP-1. Nature. 412: 300-307.
56. Marciniak, S. J., and D. Ron. 2006. Endoplasmic reticulum stress signaling in disease. Physiol. Rev. 86: 1133-1149.
57. Calkhoven, C. F., C. Muller, and A. Leutz. 2002. Translational control of gene expression and disease. Trends Mol. Med. 8: 577-583.
58. Dagon, Y., Y. Avraham, and E. M. Berry. 2006. AMPK activation regulates apoptosis, adipogenesis, and lipolysis by eIF2alpha in adipocytes. Biochem. Biophys. Res. Commun. 340: 43-47.
59. Soukas, A., N. D. Socci, B. D. Saatkamp, S. Novelli, and J. M. Friedman. 2001. Distinct transcriptional profi les of adipogenesis in vivo and in vitro. J. Biol. Chem. 276: 34167-34174.
60. Batchvarova, N., X. Z. Wang, and D. Ron. 1995. Inhibition of adipogenesis by the stress-induced protein CHOP (Gadd153). EMBO J. 14: 4654-4661.
61. Shimada, T., N. Hiramatsu, M. Okamura, K. Hayakawa, A. Kasai, J. Yao, and M. Kitamura. 2007. Unexpected blockade of adipocyte differentiation by K-7174: implication for endoplasmic reticulum stress. Biochem. Biophys. Res. Commun. 363: 355-360.
62. Lagace, D. C., and M. W. Nachtigal. 2004. Inhibition of histone deacetylase activity by valproic acid blocks adipogenesis. J. Biol. Chem. 279: 18851-18860.
63. Rubenstein, R. C., and P. L. Zeitlin. 2000. Sodium 4-phenylbutyrate downregulates Hsc70: implications for intracellular trafficking of DeltaF508-CFTR. Am. J. Physiol. Cell Physiol 278: C259-C267.
64. Iordache, C., and M. Duszyk. 2007. Sodium 4-phenylbutyrate upregulates ENaC and sodium absorption in T84 cells. Exp. Cell Res. 313: 305-311.
65. Kouraklis, G., and S. Theocharis. 2006. Histone deacetylase inhibitors: a novel target of anticancer therapy (review). Oncol. Rep. 15: 489-494.
66. Fajas, L., V. Egler, R. Reiter, J. Hansen, K. Kristiansen, M. B. Debril, S. Miard, and J. Auwerx. 2002. The retinoblastoma-histone deacetylase 3 complex inhibits PPARgamma and adipocyte differentiation. Dev. Cell. 3: 903-910.
67. Fu, M., M. Rao, T. Bouras, C. Wang, K. Wu, X. Zhang, Z. Li, T. P. Yao, and R. G. Pestell. 2005. Cyclin D1 inhibits peroxisome proliferator-activated receptor gamma-mediated adipogenesis through histone deacetylase recruitment. J. Biol. Chem. 280: 16934-16941.
68. Wiper-Bergeron, N., D. Wu, L. Pope, C. Schild-Poulter, and R. J. Hache. 2003. Stimulation of preadipocyte differentiation by steroid through targeting of an HDAC1 complex. EMBO J. 22: 2135-2145.
69. Yoo, E. J., J. J. Chung, S. S. Choe, K. H. Kim, and J. B. Kim. 2006. Down-regulation of histone deacetylases stimulates adipocyte differentiation. J. Biol. Chem. 281: 6608-6615.
70. Zuo, Y., L. Qiang, and S. R. Farmer. 2006. Activation of CCAAT/ enhancer-binding protein (C/EBP) alpha expression by C/EBP beta during adipogenesis requires a peroxisome proliferator-activated receptor-gamma-associated repression of HDAC1 at the C/ebp alpha gene promoter. J. Biol. Chem. 281: 7960-7967.
71. Kern, R. M., Z. Yang, P. S. Kim, W. W. Grody, R. K. Iyer, and S. D. Cederbaum. 2007. Arginase induction by sodium phenylbutyrate in mouse tissues and human cell lines. Mol. Genet. Metab. 90: 37-41.
72. Shack, S., A. Miller, L. Liu, P. Prasanna, A. Thibault, and D. Samid. 1996. Vulnerability of multidrug-resistant tumor cells to the aromatic fatty acids phenylacetate and phenylbutyrate. Clin. Cancer Res. 2: 865-872.
73. Camacho, L. H., J. Olson, W. P. Tong, C. W. Young, D. R. Spriggs, and M. G. Malkin. 2007. Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors. Invest. New Drugs. 25: 131-138.
74. Sung, M. W., and S. Waxman. 2007. Combination of cytotoxic-differentiation therapy with 5-fluorouracil and phenylbutyrate in patients with advanced colorectal cancer. Anticancer Res. 27: 995-1001.
75. Caruthers, R. L., and C. E. Johnson. 2007. Stability of extemporaneously prepared sodium phenylbutyrate oral suspensions. Am. J. Health Syst. Pharm. 64: 1513-1515.
76. Hines, P., G. J. Dover, and L. M. Resar. 2008. Pulsed-dosing with oral sodium phenylbutyrate increases hemoglobin F in a patient with sickle cell anemia. Pediatr. Blood Cancer. 50: 357-359.
77. Phuphanich, S., S. D. Baker, S. A. Grossman, K. A. Carson, M. R. Gilbert, J. D. Fisher, and M. A. Carducci. 2005. Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study. Neuro-oncol. 7: 177-182.
78. Resar, L. M., J. B. Segal, L. K. Fitzpatric, A. Friedmann, S. W. Brusilow, and G. J. Dover. 2002. Induction of fetal hemoglobin synthesis in children with sickle cell anemia on low-dose oral sodium phenylbutyrate therapy. J. Pediatr. Hematol. Oncol. 24: 737-741.
79. Colgan, S. M., D. Tang, G. H. Werstuck, and R. C. Austin. 2007. Endoplasmic reticulum stress causes the activation of sterol regulatory element binding protein-2. Int. J. Biochem. Cell Biol. 39: 1843-1851.
80. Wang, H., G. Kouri, and C. B. Wollheim. 2005. ER stress and SREBP-1 activation are implicated in beta-cell glucolipotoxicity. J. Cell Sci. 118: 3905-3915.
81. Kammoun, H. L., H. Chabanon, I. Hainault, S. Luquet, C. Magnan, T. Koike, P. Ferre, and F. Foufelle. 2009. GRP78 expression inhibits insulin and ER stress-induced SREBP-1c activation and reduces hepatic steatosis in mice. J. Clin. Invest. 119: 1201-1215.